head and neck cancer

The European Patent Office has issued a new patent to biotechnology company, CEL-SCI, for its lead investigational immunotherapy, which is undergoing a Phase III clinical trial for head and neck cancer. more


An integrated oncology platform from Crown Bioscience has helped to advance the preclinical development of a HERA-GITRL immunotherapy from Apogenix for non-small cell lung cancer (NSCLC) and head and neck cancer. more


Nanobiotix is expanding and accelerating its clinical development activities, including its head and neck cancer programme and immune-oncology programme. more